Comparative Pharmacology
Head-to-head clinical analysis: PEMETREXED versus PEMFEXY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMETREXED versus PEMFEXY.
PEMETREXED vs PEMFEXY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), leading to inhibition of de novo purine and pyrimidine synthesis.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis.
500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle, with folic acid and vitamin B12 supplementation.
500 mg/m2 intravenously over 10 minutes on day 1 of a 21-day cycle, in combination with cisplatin.
None Documented
None Documented
Clinical Note
moderatePemetrexed + Digoxin
"Pemetrexed may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePemetrexed + Digitoxin
"Pemetrexed may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePemetrexed + Deslanoside
"Pemetrexed may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePemetrexed + Acetyldigitoxin
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is approximately 3.5 hours in patients with normal renal function (creatinine clearance ≥60 mL/min). Clinically, half-life is prolonged in renal impairment (up to 20 hours in severe impairment), requiring dose adjustment.
Terminal elimination half-life ~17 hours (range 13-26 hours) in patients with normal renal function; prolonged to >24 hours in renal impairment. Supports every-21-day dosing.
Primarily eliminated unchanged in urine (70-90% of dose via renal excretion over 24 hours); minimal biliary/fecal excretion (<5%).
Renal excretion (70-90% unchanged drug), biliary/fecal (<5%)
Category C
Category C
Antineoplastic Antifolate
Antineoplastic Antifolate